What are the clinical features and recommended management for patients with biallelic loss‑of‑function mutations in the PPA2 gene?

PPA2 Gene-Associated Sudden Cardiac Death and Cardiomyopathy

Patients with biallelic loss-of-function mutations in PPA2 require immediate implantable cardioverter-defibrillator (ICD) placement, strict lifelong alcohol avoidance, and careful management of febrile illnesses to prevent sudden cardiac death. 1, 2, 3

Clinical Features

Cardiac Manifestations

PPA2 deficiency presents with severe cardiac phenotypes showing marked inter- and intrafamilial variability:

• Sudden cardiac arrest: Most common presentation, occurring in 15/28 documented deaths 1
• Acute heart failure: Accounts for 13/28 deaths, can present at any age from infancy to adulthood 1, 3
• Age of onset: Highly variable
  • 23 patients died before age 2 years
  • 5 patients died between ages 14-16 years
  • Adult-onset presentations documented (including a 58-year-old) 3
• Cardiomyopathy patterns: Non-ischemic cardiomyopathy with characteristic cardiac MRI findings showing subepicardial and mid-myocardial fibrosis, patchy late gadolinium enhancement 2, 3

Triggers for Cardiac Events

Three critical precipitants must be recognized:

1. Alcohol intake: Even minimal amounts trigger sudden cardiac arrest in teenagers and young adults 1, 4
2. Viral infections/febrile illness: Precipitate both sudden death and acute heart failure 1, 2, 5
3. Pyrexial episodes: Any fever-inducing condition poses risk 5

Extracardiac Features

• Recurrent rhabdomyolysis: Occurs with viral illnesses, muscle aches between episodes 2
• Progressive neurological disease: Observed in 2/6 surviving individuals 1
• Prenatal diagnosis possible: One case diagnosed prenatally with cardiomyopathy 1

Diagnostic Approach

When to Suspect PPA2 Deficiency

Consider testing in patients with:

• Unexplained cardiomyopathy in children or young adults
• Sudden cardiac arrest without clear etiology
• Recurrent cardiac symptoms with muscle involvement
• Family history of sudden cardiac death in young relatives
• Cardiac MRI showing subepicardial/mid-myocardial fibrosis WITHOUT troponin elevation 2

Genetic Testing

• Inheritance pattern: Autosomal recessive
• Molecular findings: 17 pathogenic variants identified (5 previously reported, 12 novel) 1
• Functional characterization: Recombinant PPA2 enzyme activities significantly decreased and temperature-sensitive compared to wild-type 1
• Testing strategy: Sequence PPA2 gene in probands; cascade testing in siblings and at-risk family members

Cardiac Evaluation

• Echocardiography: May show severe left ventricular systolic dysfunction (can be reversible with treatment) 3
• Cardiac MRI: Characteristic findings include diffuse myocardial fibrosis, patchy late gadolinium enhancement, persistent myocardial inflammation 2, 3
• Rhythm monitoring: Essential to detect non-sustained ventricular tachycardia 3

Management Recommendations

Primary Prevention (Asymptomatic Mutation Carriers)

ICD placement should be strongly considered even in asymptomatic carriers given the unpredictable timing and high mortality of first events. 1, 5

Secondary Prevention (Survivors of Cardiac Arrest)

1. ICD implantation: Mandatory for all survivors 3, 5
2. Heart failure management: Standard guideline-directed medical therapy when systolic dysfunction present 3

Lifestyle Modifications (Critical)

• Absolute alcohol avoidance: Must be strictly enforced throughout life, including avoidance of alcohol-containing medication preparations 1, 5
• Febrile illness management:
  • Aggressive antipyretic therapy at first sign of fever
  • Low threshold for hospitalization during viral illnesses
  • Childhood vaccinations administered in hospital setting due to pyrexia risk 5
• Activity restrictions: Specific recommendations not established, but caution warranted given sudden death risk

Monitoring Protocol

• Regular cardiac surveillance: Serial echocardiograms and rhythm monitoring
• Neurological assessment: Screen for progressive neurological signs in survivors 1
• Family screening: Test all siblings and at-risk relatives given autosomal recessive inheritance

Prognostic Information

Survival Data

Among 34 documented individuals with PPA2 mutations:

• Only 6 remain alive
• 28 died (15 from sudden cardiac arrest, 13 from acute heart failure)
• Mortality concentrated in early childhood but can occur at any age 1

Reversibility Potential

One documented case showed complete normalization of systolic function after 6 months of heart failure treatment, though ICD still required due to extensive fibrosis and arrhythmia risk 3. This suggests some cardiac manifestations may be reversible with appropriate management.

Family Counseling

Genetic counseling is essential given:

• Autosomal recessive inheritance pattern
• High mortality risk (only 6/34 documented patients alive)
• Need for cascade family screening
• Reproductive implications for siblings and future children
• Psychological impact of diagnosis on family members

The phenotypic variability means that even within families, presentation can range from sudden infant death to adult-onset reversible cardiomyopathy, making risk stratification challenging but emphasizing the need for vigilant monitoring of all mutation carriers 1, 3.